Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, β-lapachone

Melissa S. Bentle, Kathryn E. Reinicke, Ying Dong, Erik A. Bey, David A. Boothman

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Commonly used antitumor agents, such as DNA topoisomerase I/II poisons, kill cancer cells by creating nonrepairable DNA double-strand breaks (DSBs).T o repair DSBs, error-free homologous recombination (HR), and/or error-prone nonhomologous end joining (NHEJ) are activated. These processes involve the phosphatidylinositol 3′-kinase-related kinase family of serine/threonine enzymes: ataxia telangiectasia mutated (ATM), ATM- and Rad3-related for HR, and DNA-dependent protein kinase catalytic subunit (DNA-PKcs) for NHEJ. Alterations in these repair processes can cause drug/radiation resistance and increased genomic instability. β-Lapachone (β-lap; also known as ARQ 501), currently in phase II clinical trials for the treatment of pancreatic cancer, causes a novel caspase- and p53-independent cell death in cancer cells overexpressing NAD(P)H:quinone oxidoreductase-1 (NQO1). NQO1 catalyzes a futile oxidoreduction of β-lap leading to reactive oxygen species generation, DNA breaks, γ-H2AX foci formation, and hyperactivation of poly(ADP-ribose) polymerase-1, which is required for cell death. Here, we report that β-lap exposure results in NQO1-dependent activation of the MRE11-Rad50-Nbs-1 complex. In addition, ATM serine 1981, DNA-PKcs threonine 2609, and Chk1 serine 345 phosphorylation were noted; indicative of simultaneous HR and NHEJ activation. However, inhibition of NHEJ, but not HR, by genetic or chemical means potentiated β-lap lethality. These studies give insight into the mechanism by which β-lap radiosensitizes cancer cells and suggest that NHEJ is a potent target for enhancing the therapeutic efficacy of β-lap alone or in combination with other agents in cancer cells that express elevated NQO1 levels.

Original languageEnglish (US)
Pages (from-to)6936-6945
Number of pages10
JournalCancer Research
Volume67
Issue number14
DOIs
StatePublished - Jul 15 2007

Fingerprint

Homologous Recombination
Ataxia Telangiectasia
Antineoplastic Agents
DNA-Activated Protein Kinase
Serine
Catalytic Domain
Neoplasms
Cell Death
Phosphatidylinositol 3-Kinase
Type II DNA Topoisomerase
Type I DNA Topoisomerase
Phase II Clinical Trials
DNA Breaks
Double-Stranded DNA Breaks
Genomic Instability
Poisons
Protein-Serine-Threonine Kinases
Threonine
Caspases
Pancreatic Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, β-lapachone. / Bentle, Melissa S.; Reinicke, Kathryn E.; Dong, Ying; Bey, Erik A.; Boothman, David A.

In: Cancer Research, Vol. 67, No. 14, 15.07.2007, p. 6936-6945.

Research output: Contribution to journalArticle

Bentle, Melissa S. ; Reinicke, Kathryn E. ; Dong, Ying ; Bey, Erik A. ; Boothman, David A. / Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, β-lapachone. In: Cancer Research. 2007 ; Vol. 67, No. 14. pp. 6936-6945.
@article{5470972ba9e74c69b325375b5ff1faf6,
title = "Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, β-lapachone",
abstract = "Commonly used antitumor agents, such as DNA topoisomerase I/II poisons, kill cancer cells by creating nonrepairable DNA double-strand breaks (DSBs).T o repair DSBs, error-free homologous recombination (HR), and/or error-prone nonhomologous end joining (NHEJ) are activated. These processes involve the phosphatidylinositol 3′-kinase-related kinase family of serine/threonine enzymes: ataxia telangiectasia mutated (ATM), ATM- and Rad3-related for HR, and DNA-dependent protein kinase catalytic subunit (DNA-PKcs) for NHEJ. Alterations in these repair processes can cause drug/radiation resistance and increased genomic instability. β-Lapachone (β-lap; also known as ARQ 501), currently in phase II clinical trials for the treatment of pancreatic cancer, causes a novel caspase- and p53-independent cell death in cancer cells overexpressing NAD(P)H:quinone oxidoreductase-1 (NQO1). NQO1 catalyzes a futile oxidoreduction of β-lap leading to reactive oxygen species generation, DNA breaks, γ-H2AX foci formation, and hyperactivation of poly(ADP-ribose) polymerase-1, which is required for cell death. Here, we report that β-lap exposure results in NQO1-dependent activation of the MRE11-Rad50-Nbs-1 complex. In addition, ATM serine 1981, DNA-PKcs threonine 2609, and Chk1 serine 345 phosphorylation were noted; indicative of simultaneous HR and NHEJ activation. However, inhibition of NHEJ, but not HR, by genetic or chemical means potentiated β-lap lethality. These studies give insight into the mechanism by which β-lap radiosensitizes cancer cells and suggest that NHEJ is a potent target for enhancing the therapeutic efficacy of β-lap alone or in combination with other agents in cancer cells that express elevated NQO1 levels.",
author = "Bentle, {Melissa S.} and Reinicke, {Kathryn E.} and Ying Dong and Bey, {Erik A.} and Boothman, {David A.}",
year = "2007",
month = "7",
day = "15",
doi = "10.1158/0008-5472.CAN-07-0935",
language = "English (US)",
volume = "67",
pages = "6936--6945",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, β-lapachone

AU - Bentle, Melissa S.

AU - Reinicke, Kathryn E.

AU - Dong, Ying

AU - Bey, Erik A.

AU - Boothman, David A.

PY - 2007/7/15

Y1 - 2007/7/15

N2 - Commonly used antitumor agents, such as DNA topoisomerase I/II poisons, kill cancer cells by creating nonrepairable DNA double-strand breaks (DSBs).T o repair DSBs, error-free homologous recombination (HR), and/or error-prone nonhomologous end joining (NHEJ) are activated. These processes involve the phosphatidylinositol 3′-kinase-related kinase family of serine/threonine enzymes: ataxia telangiectasia mutated (ATM), ATM- and Rad3-related for HR, and DNA-dependent protein kinase catalytic subunit (DNA-PKcs) for NHEJ. Alterations in these repair processes can cause drug/radiation resistance and increased genomic instability. β-Lapachone (β-lap; also known as ARQ 501), currently in phase II clinical trials for the treatment of pancreatic cancer, causes a novel caspase- and p53-independent cell death in cancer cells overexpressing NAD(P)H:quinone oxidoreductase-1 (NQO1). NQO1 catalyzes a futile oxidoreduction of β-lap leading to reactive oxygen species generation, DNA breaks, γ-H2AX foci formation, and hyperactivation of poly(ADP-ribose) polymerase-1, which is required for cell death. Here, we report that β-lap exposure results in NQO1-dependent activation of the MRE11-Rad50-Nbs-1 complex. In addition, ATM serine 1981, DNA-PKcs threonine 2609, and Chk1 serine 345 phosphorylation were noted; indicative of simultaneous HR and NHEJ activation. However, inhibition of NHEJ, but not HR, by genetic or chemical means potentiated β-lap lethality. These studies give insight into the mechanism by which β-lap radiosensitizes cancer cells and suggest that NHEJ is a potent target for enhancing the therapeutic efficacy of β-lap alone or in combination with other agents in cancer cells that express elevated NQO1 levels.

AB - Commonly used antitumor agents, such as DNA topoisomerase I/II poisons, kill cancer cells by creating nonrepairable DNA double-strand breaks (DSBs).T o repair DSBs, error-free homologous recombination (HR), and/or error-prone nonhomologous end joining (NHEJ) are activated. These processes involve the phosphatidylinositol 3′-kinase-related kinase family of serine/threonine enzymes: ataxia telangiectasia mutated (ATM), ATM- and Rad3-related for HR, and DNA-dependent protein kinase catalytic subunit (DNA-PKcs) for NHEJ. Alterations in these repair processes can cause drug/radiation resistance and increased genomic instability. β-Lapachone (β-lap; also known as ARQ 501), currently in phase II clinical trials for the treatment of pancreatic cancer, causes a novel caspase- and p53-independent cell death in cancer cells overexpressing NAD(P)H:quinone oxidoreductase-1 (NQO1). NQO1 catalyzes a futile oxidoreduction of β-lap leading to reactive oxygen species generation, DNA breaks, γ-H2AX foci formation, and hyperactivation of poly(ADP-ribose) polymerase-1, which is required for cell death. Here, we report that β-lap exposure results in NQO1-dependent activation of the MRE11-Rad50-Nbs-1 complex. In addition, ATM serine 1981, DNA-PKcs threonine 2609, and Chk1 serine 345 phosphorylation were noted; indicative of simultaneous HR and NHEJ activation. However, inhibition of NHEJ, but not HR, by genetic or chemical means potentiated β-lap lethality. These studies give insight into the mechanism by which β-lap radiosensitizes cancer cells and suggest that NHEJ is a potent target for enhancing the therapeutic efficacy of β-lap alone or in combination with other agents in cancer cells that express elevated NQO1 levels.

UR - http://www.scopus.com/inward/record.url?scp=34547125117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547125117&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-0935

DO - 10.1158/0008-5472.CAN-07-0935

M3 - Article

C2 - 17638905

AN - SCOPUS:34547125117

VL - 67

SP - 6936

EP - 6945

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 14

ER -